Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ponticelli, C.
Right arrow Articles by Passerini, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ponticelli, C.
Right arrow Articles by Passerini, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 8-10
© 2001 European Renal Association-European Dialysis and Transplant Association


Treatment of membranous nephropathy

Claudio Ponticelli and Patrizia Passerini

Division of Nephrology, Ospedale Maggiore di Milano, Italy

Abstract

Several therapeutic approaches have been tried in patients with membranous nephropathy. Corticosteroids have been largely used, but a meta-analysis of the available controlled trials did not show any benefit of corticosteroids either in favouring remission of the nephrotic syndrome or in preventing renal dysfunction. Controversial results have been obtained with cytotoxic agents. Unfortunately, most of the available trials were small in size and had short-term follow-ups. Three controlled trials evaluated the role of a 6-month treatment with methylprednisolone and chlorambucil. The first trial showed that the 10-year renal survival rate was 92% in treated patients compared with 60% in untreated controls. A second trial compared the effects of methylprednisolone/chlorambucil with those of methylprednisolone alone. The combined treatment achieved remission of nephrotic syndrome in 64% of cases vs 38% in patients given steroids alone. A third trial showed equivalent results in patients randomized to be given methylprednisolone/chlorambucil or methylprednisolone/cyclophosphamide. A number of non-controlled studies and a randomized trial also showed the efficacy of cyclosporine in reducing proteinuria. In many but not all cases, proteinuria reappeared when cyclosporine was stopped. In conclusion, although the treatment of membranous nephropathy remains difficult, some therapeutical approaches have proved to favour remission and protect renal function

Keywords: chlorambucil; corticosteroid; cyclophosphamide; cyclosporine; membranous nephropathy

Notes

Correspondence and offprint requests to: Prof. Claudio Ponticelli, Division of Nephrology, Ospedale Maggiore di Milano, Via Commenda, 15 Padiglione Croff, 20122 Milano, Italy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
L. Senthil Nayagam, A. Ganguli, M. Rathi, H. S. Kohli, K. L. Gupta, K. Joshi, V. Sakhuja, and V. Jha
Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1926 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Coppo
Non-steroidal and non-cytotoxic therapies for nephrotic syndrome
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1793 - 1796.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. W. Ballardie
Quantitative Appraisal of Treatment Options for IgA Nephropathy
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2806 - 2809.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.